Perkins Capital Management Inc. Has $514,000 Holdings in OptimizeRx Co. (NASDAQ:OPRX)

Perkins Capital Management Inc. grew its holdings in shares of OptimizeRx Co. (NASDAQ:OPRX) by 4.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 105,813 shares of the company’s stock after acquiring an additional 4,450 shares during the quarter. Perkins Capital Management Inc.’s holdings in OptimizeRx were worth $514,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in OPRX. Quest Partners LLC increased its position in OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after buying an additional 2,414 shares during the last quarter. Barclays PLC increased its holdings in shares of OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after buying an additional 21,060 shares in the last quarter. Bullseye Asset Management LLC lifted its stake in shares of OptimizeRx by 55.6% in the 3rd quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock valued at $1,652,000 after acquiring an additional 76,458 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of OptimizeRx during the 4th quarter valued at $51,000. Institutional investors own 76.47% of the company’s stock.

Insider Buying and Selling

In other OptimizeRx news, Director James Paul Lang purchased 321,408 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was purchased at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the acquisition, the director now owns 389,452 shares in the company, valued at approximately $2,959,835.20. The trade was a 472.35 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is owned by insiders.

OptimizeRx Stock Down 1.8 %

OptimizeRx stock opened at $8.63 on Monday. The firm has a 50 day moving average price of $5.84 and a two-hundred day moving average price of $5.92. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx Co. has a 52-week low of $3.78 and a 52-week high of $14.13. The firm has a market cap of $158.97 million, a price-to-earnings ratio of -6.49 and a beta of 1.31.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on OPRX shares. B. Riley raised OptimizeRx to a “strong-buy” rating in a report on Wednesday, March 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price objective on shares of OptimizeRx in a research note on Thursday, February 6th. Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of OptimizeRx in a research report on Tuesday, December 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $6.00 price target (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Finally, Stephens started coverage on shares of OptimizeRx in a report on Friday, December 20th. They set an “equal weight” rating and a $5.50 price target on the stock. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.